Tests modified immune cells in young people with returning or resistant B-cell leukemia
Tests modified T cells targeting CD19 and CD22 in young people with leukemia.
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 130 people, planned
- Started
- 28 Dec 2022
- Expected to end
- 1 Jul 2029
- Type of study
- Interventional, 9 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- CD19/CD22-CAR-transduced T cells
- cyclophosphamide
- fludarabine
- Record updated
- 26 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults aged 3 to 39 with B-cell acute lymphoblastic leukemia or high-grade B-cell lymphoma that came back or did not respond to treatment. It tests CAR T cells made from their own blood.
- Age
- 3 to 39 years
- Sex
- All sexes can join.
- Disease stage
- B-cell ALL (not only in the testis or CNS), CML with ALL transformation, or high-grade B-cell lymphoma. The disease came back or did not respond. Signs of at least minimal residual disease or PET-avid lymphoma are needed. CNS 1 and 2 disease can join.
- Earlier treatment
- At least one standard chemotherapy regimen and at least one salvage treatment. Philadelphia chromosome-positive ALL must have failed a tyrosine kinase inhibitor. People must be unable to have stem cell transplant, refuse it, or have relapsed after it. People must also be unable to get, or have failed, a commercial CD19 CAR T-cell treatment.
- Biomarker or test result
- CD19 must be found on more than 15% of cancer cells by immunohistochemistry, or more than 80% by flow cytometry, and CD22 must be confirmed (cohorts A1b, B1b, C2b). For B-ALL cohorts D1b and 2, CD19 or CD22 must be confirmed.
Main reasons for not taking part
- CNS3 disease, worsening nerve signs from CNS disease, or active CNS lymphoma
- 50,000 or more blasts/microL (hyperleukocytosis)
- Positive pregnancy test at screening
- Active HIV, hepatitis B or hepatitis C infection
- Active second cancer (with limited exceptions)
The registry criteria, word for word
Show all 22 criteriaShow less
Who cannot take part
- Participants with CNS3 disease, progressing neurologic signs* of CNS disease, radiologically detected active CNS lymphoma (*resolving manifestation or persistent and/or irreversible findings from prior CNS involvement (e.g., blindness) is not exclusionary)
- Active second malignancy other than in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least two years previously and participant is in remission
- Positive HIV antibodies consistent with active HIV
- Positive hepatitis C antibodies or positive Hepatitis B surface antigen (HbsAG) indicative of current/active HCV/HBV
- History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells
- Uncontrolled, symptomatic, intercurrent illness or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the participant
- Positive serum or urine beta-HCG pregnancy test performed at screening
- Participants will be excluded based on prior therapy if they fail to meet following washout criteria:; Therapy: Systemic Chemotherapy, anti-neoplastic agents, antibody- based therapies; Washout*: >=2 weeks; Exceptions: 6 weeks for clofarabine or nitrosoureas; No washout for prior intrathecal chemotherapy, steroid therapy, hydroxyurea (no dose increases within prior 2 weeks) or ALL maintenance-type chemotherapy (vincristine, 6-mercaptopurine, oral methotrexate, or a tyrosine kinase inhibitor for participants with Ph+ ALL) provided there is recovery from any acute toxic effects; Therapy: Radiation; Washout*: >=3 weeks; Exceptions: No time restriction with radiation therapy if the volume of bone marrow treated is less than 10% and the participant has measurable/evaluable disease outside the radiation window; Therapy: Allogeneic Stem Cell Transplant; Washout*: >= 100 days since SCT; >= 30 days since completion of immunosuppression; >= 6 weeks since donor lymphocyte infusion (DLI); Exceptions: Cannot have evidence of active graft-versus-host disease (GVHD) requiring systemic immunosuppression; Therapy: CAR T-Cell Therapy or other Adoptive Cell Therapy; Washout*: > 30 days post infusion; Washout: Time between therapy and apheresis
- Participants meeting any of the following criteria are not eligible for participation in the study:
- Hyperleukocytosis (>= 50,000 blasts/microL)
Other criteria
- INCLUSION CRITERIA:
- Diagnosis; Participant must:; Have pathology confirmed B cell ALL (not isolated to the testis or CNS), CML with ALL transformation, or high-grade lymphoma (e.g., Burkitt's lymphoma, B-lymphoblastic lymphoma, diffuse large B-cell lymphoma, inclusive of low-grade lymphoma that has transformed to high grade disease); and; Have relapsed or been refractory after at least one standard chemotherapy regimen and at least one salvage treatment. Participants with Philadelphia chromosome + ALL must have failed prior tyrosine kinase inhibitor; and; Be ineligible for allogeneic stem cell transplant (SCT), have refused SCT, or have recurred after SCT; and; Be unable to access (in a timely manner), ineligible for, or have relapsed/failed after or not responded to a commercially available CD19 CAR T-cell construct; and; Have evidence of at least minimal residual disease or PET-avid disease (lymphoma) at the time of enrollment
- CD22/CD19 expression; Cohorts A1b, B1b, C2b; CD19 must be detected on >15% of the malignant cells by immunohistochemistry or > 80% by flow cytometry; CD22 positivity must be confirmed; Cohorts D1b, 2 B-ALL; CD19 or CD22 positivity must be confirmed; Age >= 3 years of age and <=39 years of age at time of enrollment; Clinical Performance status: Participants >= 16 years of age: Karnofsky >= 50%; Participants < 16 years of age: Lansky scale >= 50%
- Participants must have adequate organ and marrow function as defined below:; leukocytes >= 750/mcL*; platelets >= 50,000/mcL*; total bilirubin <=2 X ULN (except in the case of participants with documented Gilbert's disease > 3x ULN); AST(SGOT)/ALT(SGPT) <=10 X institutional upper limit of normal; creatinine <= the maximum for age listed in the table below OR; measured creatinine clearance >=60 mL/min/1.73 m\^2 for participants with creatinine levels above the max listed below per age; Age (Years) <= 5 / Maximum Serum Creatinine (mg/dL) <= 0.8; Age (Years) 6 to <= 10 / Maximum Serum Creatinine (mg/dL) <= 1.0; Age (Years) >10 / Maximum Serum Creatinine (mg/dL) <= 1.2; a participant will not be excluded because of pancytopenia >= Grade 3 if it is due to underlying bone marrow involvement by leukemia
- Central nervous system (CNS) Status
- Participants with leukemia with CNS 1 and 2 disease are eligible in the absence of exclusion criteria
- Participants of child-bearing or child-fathering potential must be willing to practice effective birth control from the time of enrollment until 12 months following completion of study treatment for women and for 4 months following completion of study treatment for men
- Participants who are breastfeeding or plan to breastfeed must agree to discontinue/postpone breastfeeding while on study therapy and until 1 month after the administration of CAR
- Cardiac function: Left ventricular ejection fraction >= 45% or fractional shortening >=28%
- Pulmonary Function; Baseline oxygen saturation >92% on room air at rest
- Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document
- Ability and willingness of participant or Legally Authorized Representative (LAR) to co- enroll on 15-C-0028: Follow-up Evaluation for Gene-Therapy Related Delayed Adverse Events after Participation in Pediatric Oncology Branch Clinical Trials
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 39 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: NCI Ped LeukemiaLymph Cell Tx TmTaking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses.
Objective:
To test chimeric antigen receptor (CAR) therapy. CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD19 and CD22 at the same time. CD19 and CD22 are proteins found on the surface of most types of ALL.
Eligibility:
People aged 3 to 39 with ALL or related B-cell lymphoma that has not been cured by standard therapy.
Design:
Participants will be screened. This will include:
Physical exam
Blood and urine tests
Tests of their lung and heart function
Imaging scans
Bone marrow biopsy. A large needle will be inserted into the body to draw some tissues from the interior of a bone.
Lumbar puncture. A needle will be inserted into the lower back to draw fluid from the area around the spinal cord.
Participants will undergo apheresis. Their blood will circulate through a machine that separates blood into different parts. The portion containing T cells will be collected; the remaining cells and fluids will be returned to the body. The T cells will be changed in a laboratory to make them better at fighting cancer cells.
Participants will receive chemotherapy starting 4 or 5 days before the CAR treatment.
Participants will be admitted to the hospital. Their own modified T cells will be returned to their body.
Participants will visit the clinic 2 times a week for 28 days after treatment. Follow-up will continue for 15 years....
The 9 groups in the trial
- 1/Phase I Dose Escalation-with standard LD - CLOSEDTreatment being tested
CD19/CD22-CAR-transduced T cells at escalating dose + standard LD (75 mg/mg2 Flu+ 900 mg/m2 Cy)
Treatment: CD19/CD22-CAR-transduced T cells, cyclophosphamide, and fludarabine
- 1b/Phase 1 Dose Escalation - low disease burdenTreatment being tested
CD19/CD22-CAR-transduced T cells
Treatment: CD19/CD22-CAR-transduced T cells, cyclophosphamide, and fludarabine
- 2/Phase I Dose Escalation- with intensified LD - CLOSEDTreatment being tested
CD19/CD22-CAR-transduced T cells + standard LD (120 mg/m2 Flu + 1200 mg/m2 Cy)
Treatment: CD19/CD22-CAR-transduced T cells, cyclophosphamide, and fludarabine
- 2b/Phase 1 Dose Escalation - high disease burdenTreatment being tested
CD19/CD22-CAR-transduced T cells
Treatment: CD19/CD22-CAR-transduced T cells, cyclophosphamide, and fludarabine
- 3/Phase II Dose Expansion- with low disease burden - CLOSEDTreatment being tested
CD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD
Treatment: CD19/CD22-CAR-transduced T cells, cyclophosphamide, and fludarabine
- 3b Phase I Dose Escalation: Either CD19 or CD22 positivityTreatment being tested
CD19/CD22-CAR-transduced T cells
Treatment: CD19/CD22-CAR-transduced T cells, cyclophosphamide, and fludarabine
- 4/Phase II Dose Expansion- with high disease burden - CLOSEDTreatment being tested
CD19/CD22-CAR-transduced T cells at MTD/or highest dose administered with LD regimen #2
Treatment: CD19/CD22-CAR-transduced T cells, cyclophosphamide, and fludarabine
- 4b Phase II Dose Expansion in B-ALL/B-LBLTreatment being tested
CD19/CD22-CAR-transduced T cells at RP2D
Treatment: CD19/CD22-CAR-transduced T cells, cyclophosphamide, and fludarabine
- A/Pre-treatmentNo study treatment, for comparison
All participants enrolled on the study prior to treatment initiation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
- Plain-language title
- Tests modified immune cells in young people with returning or resistant B-cell leukemiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05442515, who can take part
- Record updated
- 26 October 2026